Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Assaf-Harofeh Medical Center |
---|---|
Information provided by: | Assaf-Harofeh Medical Center |
ClinicalTrials.gov Identifier: | NCT00592618 |
Sleep studies in ESRD patients have identified increased prevalence of Sleep Apnea. Based on current knowledge, treatment aimed at reducing oxidative stress might improve Sleep Apnea in HD patients. The aim of our study is to investigate the effect of N-acetylsysteine on Sleep Apnea in HD patients.
Condition | Intervention |
---|---|
ESRD Sleep Apnea |
Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Safety Study |
Ages Eligible for Study: | 20 Years to 85 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Patients will be excluded from the study if they are:
Contact: Leonid S Feldman, MD | +972-8-9779383 | leonidf@asaf.health.gov.il |
Israel | |
Nephrology Division, Assaf Harofeh Medical Center | |
Zerifin, Israel, 70300 |
Principal Investigator: | Leonid S Feldman, MD | Assaf Harofeh MC |
Study ID Numbers: | 346147SLEEP |
Study First Received: | January 1, 2008 |
Last Updated: | January 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00592618 |
Health Authority: | Israel: Ministry of Health |
ESRD Hemodialysis Sleep Apnea Hemodialysis |
Signs and Symptoms Sleep Apnea Syndromes Respiratory Tract Diseases Apnea Respiration Disorders Acetylcysteine |
Dyssomnias Sleep Disorders Signs and Symptoms, Respiratory N-monoacetylcystine Sleep Disorders, Intrinsic |
Respiratory System Agents Anti-Infective Agents Antioxidants Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Antiviral Agents |
Protective Agents Pharmacologic Actions Expectorants Therapeutic Uses Free Radical Scavengers Antidotes |